;PMID: 10653207
;source_file_1911.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..44] = [t:0..44]
;1)sentence:[e:50..106] = [t:50..106]
;2)section:[e:110..163] = [t:110..163]
;3)section:[e:167..301] = [t:167..301]
;4)sentence:[e:305..403] = [t:305..403]
;5)sentence:[e:404..530] = [t:404..530]
;6)sentence:[e:531..671] = [t:531..671]
;7)sentence:[e:672..900] = [t:672..900]
;8)sentence:[e:901..960] = [t:901..960]
;9)sentence:[e:961..1074] = [t:961..1074]
;10)sentence:[e:1075..1186] = [t:1075..1186]
;11)section:[e:1190..1235] = [t:1190..1235]

;section 0 Span:0..44
;J Clin Psychopharmacol. 2000 Feb;20(1):43-5.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Clin) (NNP:[7..22] Psychopharmacol)
        (.:[22..23] .) (CD:[24..28] 2000) (CC:[29..36] Feb;20-LRB-)
        (CD:[36..37] 1) (-RRB-:[37..38] -RRB-) (CD:[38..41] :43) (::[41..43] -5)
        (.:[43..44] .)))

;sentence 1 Span:50..106
;Cytochrome P450 2D6 and treatment of codeine dependence.
;[50..69]:cyp450:"Cytochrome P450 2D6"
;[87..94]:substance:"codeine"
(SENT
  (NP-HLN
    (NP (NN:[50..60] Cytochrome) (NN:[61..65] P450) (NN:[66..69] 2D6))
    (CC:[70..73] and)
    (NP
      (NP (NN:[74..83] treatment))
      (PP (IN:[84..86] of)
        (NP (NN:[87..94] codeine) (NN:[95..105] dependence))))
    (.:[105..106] .)))

;section 2 Span:110..163
;Romach MK, Otton SV, Somer G, Tyndale RF, Sellers EM.
(SEC
  (FRAG (NNP:[110..116] Romach) (NNP:[117..119] MK) (,:[119..120] ,)
        (NNP:[121..126] Otton) (NNP:[127..129] SV) (,:[129..130] ,)
        (NNP:[131..136] Somer) (NNP:[137..138] G) (,:[138..139] ,)
        (NNP:[140..147] Tyndale) (NNP:[148..150] RF) (,:[150..151] ,)
        (NNP:[152..159] Sellers) (NN:[160..162] EM) (.:[162..163] .)))

;section 3 Span:167..301
;Department of Psychiatry, Centre for Research in Women's Health, University
;of  Toronto, Ontario, Canada. myroslava.romach@utoronto.ca
(SEC
  (FRAG (NNP:[167..177] Department) (IN:[178..180] of)
        (NNP:[181..191] Psychiatry) (,:[191..192] ,) (NNP:[193..199] Centre)
        (IN:[200..203] for) (NNP:[204..212] Research) (IN:[213..215] in)
        (NNP:[216..221] Women) (POS:[221..223] 's) (NNP:[224..230] Health)
        (,:[230..231] ,) (NNP:[232..242] University) (IN:[243..245] of)
        (NNP:[247..254] Toronto) (,:[254..255] ,) (NNP:[256..263] Ontario)
        (,:[263..264] ,) (NNP:[265..271] Canada) (.:[271..272] .)
        (NNP:[273..282] myroslava) (NNP:[282..301] .romach@utoronto.ca)))

;sentence 4 Span:305..403
;Oral opioid analgesics such as codeine are used extensively worldwide and are
; frequently misused.
;[310..327]:substance:"opioid analgesics"
;[336..343]:substance:"codeine"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[305..309] Oral)
         (JJ:[310..316] opioid) (NNS:[317..327] analgesics))
      (PP (JJ:[328..332] such) (IN:[333..335] as)
        (NP (NN:[336..343] codeine))))
    (VP
      (VP (VBP:[344..347] are)
        (VP (VBN:[348..352] used)
          (NP-1 (-NONE-:[352..352] *))
          (ADVP (RB:[353..364] extensively))
          (ADVP-LOC (RB:[365..374] worldwide))))
      (CC:[375..378] and)
      (VP (VBP:[379..382] are)
        (VP
          (ADVP-TMP (RB:[384..394] frequently))
          (VBN:[395..402] misused)
          (NP-1 (-NONE-:[402..402] *)))))
    (.:[402..403] .)))

;sentence 5 Span:404..530
;Codeine is a substrate of CYP2D6, a genetically polymorphic  P450 enzyme, and
;is metabolized to the more potent drug morphine.
;[404..411]:substance:"Codeine"
;[417..426]:substance:"substrate"
;[430..436]:cyp450:"CYP2D6"
;[465..476]:cyp450:"P450 enzyme"
;[516..520]:substance:"drug"
;[521..529]:substance:"morphine"
(SENT
  (S
    (NP-SBJ-1 (NN:[404..411] Codeine))
    (VP
      (VP (VBZ:[412..414] is)
        (NP-PRD
          (NP (DT:[415..416] a) (NN:[417..426] substrate))
          (PP (IN:[427..429] of)
            (NP
              (NP (NN:[430..436] CYP2D6))
              (,:[436..437] ,)
              (NP (DT:[438..439] a)
                (ADJP (RB:[440..451] genetically) (JJ:[452..463] polymorphic))
                 (NN:[465..469] P450) (NN:[470..476] enzyme))))))
      (,:[476..477] ,) (CC:[478..481] and)
      (VP (VBZ:[482..484] is)
        (VP (VBN:[485..496] metabolized)
          (NP-1 (-NONE-:[496..496] *))
          (PP (TO:[497..499] to)
            (NP
              (NP (DT:[500..503] the)
                (ADJP (RBR:[504..508] more) (JJ:[509..515] potent))
                (NN:[516..520] drug))
              (NP (NN:[521..529] morphine)))))))
    (.:[529..530] .)))

;sentence 6 Span:531..671
;CYP2D6  activity can be inhibited by fluoxetine, and the inhibition of
;morphine  formation may help individuals reduce their use of codeine.
;[531..537]:cyp450:"CYP2D6"
;[568..578]:substance:"fluoxetine"
;[602..610]:substance:"morphine"
;[663..670]:substance:"codeine"
(SENT
  (S
    (S
      (NP-SBJ-2 (NN:[531..537] CYP2D6) (NN:[539..547] activity))
      (VP (MD:[548..551] can)
        (VP (VB:[552..554] be)
          (VP (VBN:[555..564] inhibited)
            (NP-2 (-NONE-:[564..564] *))
            (PP (IN:[565..567] by)
              (NP-LGS (NN:[568..578] fluoxetine)))))))
    (,:[578..579] ,) (CC:[580..583] and)
    (S
      (NP-SBJ
        (NP (DT:[584..587] the) (NN:[588..598] inhibition))
        (PP (IN:[599..601] of)
          (NP (NN:[602..610] morphine) (NN:[612..621] formation))))
      (VP (MD:[622..625] may)
        (VP (VB:[626..630] help)
          (S
            (NP-SBJ (NNS:[631..642] individuals))
            (VP (VBP:[643..649] reduce)
              (NP
                (NP (PRP$:[650..655] their) (NN:[656..659] use))
                (PP (IN:[660..662] of)
                  (NP (NN:[663..670] codeine)))))))))
    (.:[670..671] .)))

;sentence 7 Span:672..900
;Fourteen long-term  users of oral opiates (principally codeine) were assessed
;for an open-label  pilot treatment study of fluoxetine 20 mg/day combined
;with a brief behavioral  intervention and structured tapering of the opiate.
;[706..713]:substance:"opiates"
;[727..734]:substance:"codeine"
;[794..804]:substance:"fluoxetine"
;[805..807]:quantitative-value:"20"
;[808..814]:quantitative-units:"mg/day"
;[893..899]:substance:"opiate"
(SENT
  (S
    (NP-SBJ-1
      (NP (CD:[672..680] Fourteen)
        (NML (JJ:[681..685] long) (HYPH:[685..686] -) (NN:[686..690] term))
        (NNS:[692..697] users))
      (PP (IN:[698..700] of)
        (NP
          (NP (JJ:[701..705] oral) (NNS:[706..713] opiates))
          (NP (-LRB-:[714..715] -LRB-) (RB:[715..726] principally)
              (NN:[727..734] codeine) (-RRB-:[734..735] -RRB-)))))
    (VP (VBD:[736..740] were)
      (VP (VBN:[741..749] assessed)
        (NP-1 (-NONE-:[749..749] *))
        (PP (IN:[750..753] for)
          (NP
            (NP (DT:[754..756] an)
              (NML (JJ:[757..761] open) (HYPH:[761..762] -)
                   (NN:[762..767] label))
              (JJ:[769..774] pilot) (NN:[775..784] treatment)
               (NN:[785..790] study))
            (PP (IN:[791..793] of)
              (NP
                (NP
                  (NP (NN:[794..804] fluoxetine))
                  (NP
                    (NP (CD:[805..807] 20) (NN:[808..810] mg))
                    (PP (SYM:[810..811] /)
                      (NP (NN:[811..814] day)))))
                (VP (VBN:[815..823] combined)
                  (NP (-NONE-:[823..823] *))
                  (PP (IN:[824..828] with)
                    (NP
                      (NP (DT:[829..830] a) (JJ:[831..836] brief)
                          (JJ:[837..847] behavioral)
                          (NN:[849..861] intervention))
                      (CC:[862..865] and)
                      (NP
                        (NP (VBN:[866..876] structured)
                            (VBG:[877..885] tapering))
                        (PP (IN:[886..888] of)
                          (NP (DT:[889..892] the) (NN:[893..899] opiate)))))))))))))
    (.:[899..900] .)))

;sentence 8 Span:901..960
;Eight subjects entered and  completed the 8-week treatment.
;[943..944]:quantitative-value:"8"
;[945..949]:quantitative-units:"week"
(SENT
  (S
    (NP-SBJ (CD:[901..906] Eight) (NNS:[907..915] subjects))
    (VP (VBD:[916..923] entered) (CC:[924..927] and) (VBD:[929..938] completed)
      (NP-1 (DT:[939..942] the)
        (NML (CD:[943..944] 8) (HYPH:[944..945] -) (NN:[945..949] week))
        (NN:[950..959] treatment)))
    (.:[959..960] .)))

;sentence 9 Span:961..1074
;Opiate use decreased by 30% to 100% of baseline  use (p < 0.0001) in parallel
;with a decrease in CYP2D6 activity.
;[961..967]:substance:"Opiate"
;[985..988]:quantitative-value:"30%"
;[992..996]:quantitative-value:"100%"
;[1058..1064]:cyp450:"CYP2D6"
(SENT
  (S
    (NP-SBJ (NN:[961..967] Opiate) (NN:[968..971] use))
    (VP (VBD:[972..981] decreased)
      (PP-EXT (IN:[982..984] by)
        (NP
          (NP
            (NP (CD:[985..987] 30) (NN:[987..988] %))
            (TO:[989..991] to)
            (NP (CD:[992..995] 100) (NN:[995..996] %)))
          (PP (IN:[997..999] of)
            (NP (NN:[1000..1008] baseline) (NN:[1010..1013] use)))))
      (PRN (-LRB-:[1014..1015] -LRB-)
        (S
          (NP-SBJ (NN:[1015..1016] p))
          (VP (SYM:[1017..1018] <)
            (NP (CD:[1019..1025] 0.0001))))
        (-RRB-:[1025..1026] -RRB-))
      (PP (IN:[1027..1029] in)
        (NP
          (NP (NN:[1030..1038] parallel))
          (PP (IN:[1039..1043] with)
            (NP
              (NP (DT:[1044..1045] a) (NN:[1046..1054] decrease))
              (PP (IN:[1055..1057] in)
                (NP (NN:[1058..1064] CYP2D6) (NN:[1065..1073] activity))))))))
    (.:[1073..1074] .)))

;sentence 10 Span:1075..1186
;Fluoxetine may  have a role in the treatment of opiate dependence by
;decreasing  opiate-reinforcing properties.
;[1075..1085]:substance:"Fluoxetine"
;[1123..1129]:substance:"opiate"
;[1156..1162]:substance:"opiate"
(SENT
  (S
    (NP-SBJ (NN:[1075..1085] Fluoxetine))
    (VP (MD:[1086..1089] may)
      (VP (VB:[1091..1095] have)
        (NP (DT:[1096..1097] a) (NN:[1098..1102] role))
        (PP (IN:[1103..1105] in)
          (NP
            (NP (DT:[1106..1109] the) (NN:[1110..1119] treatment))
            (PP (IN:[1120..1122] of)
              (NP (NN:[1123..1129] opiate) (NN:[1130..1140] dependence)))))
        (PP-MNR (IN:[1141..1143] by)
          (S-NOM
            (NP-SBJ (-NONE-:[1143..1143] *))
            (VP (VBG:[1144..1154] decreasing)
              (NP
                (NML (NN:[1156..1162] opiate) (HYPH:[1162..1163] -)
                     (VBG:[1163..1174] reinforcing))
                (NNS:[1175..1185] properties)))))))
    (.:[1185..1186] .)))

;section 11 Span:1190..1235
;PMID: 10653207 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1190..1194] PMID) (::[1194..1195] :) (CD:[1196..1204] 10653207)
        (NN:[1205..1206] -LSB-) (NNP:[1206..1212] PubMed) (::[1213..1214] -)
        (NN:[1215..1222] indexed) (IN:[1223..1226] for)
        (NNP:[1227..1235] MEDLINE-RSB-)))
